MP22-15 DEPRESSION IN PROSTATE CANCER PATIENTS STARTING ANDROGEN DEPRIVATION THERAPY
Bibliographic record
Abstract
You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II (MP22)1 Apr 2019MP22-15 DEPRESSION IN PROSTATE CANCER PATIENTS STARTING ANDROGEN DEPRIVATION THERAPY Gagan Fervaha*, Jason Izard, Dean Tripp, Selina Rajan, Sarah Karampatos, Bobby Shayegan, Edward Matsumoto, Tamim Niazi, Annabel Chen-Tournoux, Vincent Fradet, Yves Fradet, Emmanuelle Duceppe, Luke Lavallee, Christopher Johnson, Joseph Chin, Darin Gopaul, Margot Davis, Jehnonathan Pinthus, Darryl Leong, and Robert Siemens Gagan Fervaha*Gagan Fervaha* More articles by this author , Jason IzardJason Izard More articles by this author , Dean TrippDean Tripp More articles by this author , Selina RajanSelina Rajan More articles by this author , Sarah KarampatosSarah Karampatos More articles by this author , Bobby ShayeganBobby Shayegan More articles by this author , Edward MatsumotoEdward Matsumoto More articles by this author , Tamim NiaziTamim Niazi More articles by this author , Annabel Chen-TournouxAnnabel Chen-Tournoux More articles by this author , Vincent FradetVincent Fradet More articles by this author , Yves FradetYves Fradet More articles by this author , Emmanuelle DuceppeEmmanuelle Duceppe More articles by this author , Luke LavalleeLuke Lavallee More articles by this author , Christopher JohnsonChristopher Johnson More articles by this author , Joseph ChinJoseph Chin More articles by this author , Darin GopaulDarin Gopaul More articles by this author , Margot DavisMargot Davis More articles by this author , Jehnonathan PinthusJehnonathan Pinthus More articles by this author , Darryl LeongDarryl Leong More articles by this author , and Robert SiemensRobert Siemens More articles by this author View All Author Informationhttps://doi.org/10.1097/01.JU.0000555600.69863.72AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVES: Androgen deprivation therapy (ADT) for the treatment of prostate cancer has been shown, albeit not consistently, to be related to specific consequences such as incident depression. The presence of depressive symptoms in patients with advanced disease eligible for ADT is less well understood. The current study was undertaken to estimate the prevalence and predictors of depression in a contemporary sample of patients beginning ADT. METHODS: Data from the current study were drawn from the RADICAL PC study, a parent prospective cohort study conducted across 13 sites in Canada. Men with prostate cancer initiating ADT for the first time were recruited. Depressive symptoms were evaluated using the 9 item version of the Patient Health Questionnaire (PHQ-9). A score of 8 or higher on this scale represents clinically relevant depressive symptoms. To evaluate predictors of depressive symptoms, a logistic regression model was constructed including biological, psychological, and social predictor variables. RESULTS: Data from 407 patients were available at the time of this analysis. Of these, 43 (10.6%) endorsed clinically significant burden of depressive symptoms. Two variables were identified as independent predictors of depression - poor functional status (OR=5.18, p<0.001) increased depression risk, whereas being retired was found to be protective (OR=0.37, p=0.03). Indicators of advanced disease (e.g. presence of metastatic disease) were not associated with depression in either univariate or multivariate models. CONCLUSIONS: Our multi-centre study of depressive symptoms among prostate cancer patients starting ADT shows that these symptoms are already present in a sizeable sample of men. These do not seem to be affected by disease-related indicators, but rather are better predicted by psychosocial variables. Clinicians should be suspicious of poor psychological functioning especially among those prostate cancer patients with poorer functional status. Moving forward, it will be important to document the incidence and change in depressive symptoms as these patients begin ADT and are followed prospectively. Source of Funding: Prostate Cancer Canada Kingston, Canada; Hamilton, Canada; Hamiilton, Canada; Montreal, Canada; Quebec City, Canada; Montreal, Canada; Ottawa, Canada; London, Canada; Kitchener, Canada; Vancouver, Canada; Hamilton, Canada; Kingston, Canada© 2019 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 201Issue Supplement 4April 2019Page: e322-e322 Advertisement Copyright & Permissions© 2019 by American Urological Association Education and Research, Inc.MetricsAuthor Information Gagan Fervaha* More articles by this author Jason Izard More articles by this author Dean Tripp More articles by this author Selina Rajan More articles by this author Sarah Karampatos More articles by this author Bobby Shayegan More articles by this author Edward Matsumoto More articles by this author Tamim Niazi More articles by this author Annabel Chen-Tournoux More articles by this author Vincent Fradet More articles by this author Yves Fradet More articles by this author Emmanuelle Duceppe More articles by this author Luke Lavallee More articles by this author Christopher Johnson More articles by this author Joseph Chin More articles by this author Darin Gopaul More articles by this author Margot Davis More articles by this author Jehnonathan Pinthus More articles by this author Darryl Leong More articles by this author Robert Siemens More articles by this author Expand All Advertisement PDF downloadLoading ...
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.021 | 0.003 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".